Estée Lauder Earnings Beat, China Demand Raises Outlook

Estée Lauder earnings beat Q4 estimates and raised fiscal 2027 guidance; premium fragrances and China demand widened margins and spurred trading momentum.

August 19, 2026·3 min read
View all news articles
Flat-vector perfume bottle fused with an upward glow to show Estée Lauder earnings momentum from fragrances and China demand.

KEY TAKEAWAYS

  • Beat Q4 expectations and raised fiscal 2027 adjusted EPS to $3.10-$3.35 with higher margin targets.
  • Premium fragrances and mainland China demand widened margins and narrowed a quarterly loss.
  • Completed PRGP approvals and tariff refunds supported margin recovery and $1.2B gross benefits.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

The Estée Lauder Companies Inc. (NYSE: EL) reported fiscal 2026 results on Aug. 19, 2026, beating expectations as premium-fragrance strength and stronger mainland China demand narrowed a quarterly loss, widened margins, and prompted a raised fiscal 2027 outlook. The company showed renewed momentum with margin expansion and a reduced quarterly loss.

Results and Fiscal 2027 Outlook

For the fiscal year ended June 30, 2026, Estée Lauder reported net sales of approximately $15.1 billion, up about 5% from the prior year, with organic net sales rising 3%. The company posted a profit of $182 million, or $0.50 per share, and full-year adjusted diluted earnings per share (EPS) of $2.51, compared with $1.51 a year earlier. Gross profit reached about $11.4 billion, with gross margin increasing to 75.5% from 74.0%. Adjusted operating margin expanded by 320 basis points to 11.2%. President and CEO Stéphane de La Faverie said, "I am incredibly proud of our team for delivering fiscal 2026 results ahead of the expectations we had to start the year."

In the quarter ended June 30, reported revenue rose 6% to $3.6 billion, exceeding consensus estimates near $3.5 billion. Organic net sales grew 5%. The company recorded a net loss of $116 million, or $0.32 per share, while adjusted EPS was $0.39, beating the consensus of $0.32. This marked the fourth consecutive quarter of organic sales growth, with gains across most categories and regions.

Estée Lauder issued fiscal 2027 guidance calling for organic net sales growth of 3%–5%, an adjusted operating margin of 12.7%–13.5% (up from a preliminary 12.5%–13.0% range), and adjusted EPS of $3.10–$3.35. The midpoint of the EPS range exceeds analysts’ average estimate. Management attributed the outlook to continued leverage on non-consumer-facing expenses, modest gross-margin expansion, and benefits from the company’s operating model.

Fragrance, China Demand, and Restructuring

Fragrance was the standout category, with organic net sales up 10% for the full year, led by luxury brands Le Labo, TOM FORD, and KILIAN PARIS. Mainland China net sales grew 9% organically, driven by value-share gains across fragrance, skin care, and makeup. All four geographic regions posted net sales growth for both the quarter and full year, with the Americas boosted by North America’s return to growth.

The company completed approvals for the restructuring component of its Profit Recovery and Growth Plan (PRGP) as of June 30. The plan is expected to deliver gross benefits of about $1.2 billion and a net reduction of approximately 10,000 positions. Estée Lauder said it fully established its One ELC operating model with leading external partners by year-end.

The company reported incremental tariffs of $102 million in gross impact for fiscal 2026, mostly in cost of sales, partially offset by a $38 million refund benefit in the fourth quarter tied to measures under the International Emergency Economic Powers Act. The board declared a quarterly dividend of $0.35 per share, payable Sept. 15, 2026, to shareholders of record on Aug. 31.

Management framed the results and completed restructuring as evidence that its multi-year turnaround and profit recovery plan is gaining traction.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Merck Moderna Melanoma Vaccine Meets Topline Goals

Merck Moderna Melanoma Vaccine Meets Topline Goals

Merck Moderna melanoma vaccine met primary and key secondary endpoints; companies will present data and engage regulators, creating a filing catalyst.

Keysight Q3 Earnings Lift Outlook On AI Demand

Keysight Q3 Earnings Lift Outlook On AI Demand

Keysight Q3 earnings show record revenue as management cites AI data-center demand and lifts Q4 and FY2026 outlook, reinforcing orders momentum.

SK Hynix Buyback Boosts Shareholder Returns

SK Hynix Buyback Boosts Shareholder Returns

SK Hynix buyback follows record AI-driven results and tightens public float, boosting buyback flows and reinforcing investor positioning.

Lowe's Q2 2026 Results: Flat EPS, Trimmed Outlook

Lowe's Q2 2026 Results: Flat EPS, Trimmed Outlook

Lowe's Q2 2026 results show flat EPS and modest comps and updated 2026 guidance to the low end, trimming upside and pressuring investor expectations.

Palantir Q2 2026 Earnings Fuel Valuation Debate

Palantir Q2 2026 Earnings Fuel Valuation Debate

Palantir Q2 2026 earnings showed accelerating AI revenue and raised FY guidance, tightening the valuation debate and trading risk around positioning.

Target Q2 Earnings Due Before Market Open

Target Q2 Earnings Due Before Market Open

Target Q2 earnings arrive Aug. 19 before U.S. open; report will judge if sales rebound and raised outlook sustain margins and comps amid elevated options.